lobbying_activities: 1918683

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1918683	1339f8fc-be05-4e23-b069-05657407563a	Q4	KOUNTOUPES DENHAM CARR & REID, LLC	320918	ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)	2016	fourth_quarter	PHA	Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program, H.R.2841, FAST Generics Act of 2015 and S.3056, The CREATES Act, access to samples for generic testing, including S.3455, the Pharmaceutical Supply and Value Enhancement (SAVE) Act. The 21st Century Cures Act included in H. R. 2028, Further Continuing and Security Assistance Appropriations Act for Fiscal Year 2017. Affordability and pricing of pharmaceuticals. Issues related to drug takeback and opioid addiction. H. R. 4931, The Pharmaceutical Stewardship Act of 2016 and S.2977, The Budgeting for Opioid Addiction Treatment Act.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office	60000		0	0	2017-01-18T15:28:16-05:00